Cognitive Dysfunction, Cognitive Disorder
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases
A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns
Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease
INSIDE: Intervention in Nutritional Supplementation to Improve Cognitive Decline in Elderly.
The Effect of Two Different Modes of Anaesthesia Mainantance on Postoperative Delirium